

5:15 PM – 6:45 PM Exhibit Hall (220C)

Presenters of featured posters will be present during poster tours to explain their work. Tours take place at the end of the day on Tuesday and Wednesday. Tour sign-up required (see sheets in front of main entrance to Exhibit Hall at 220D). Meeting point at first poster of tour at 5:15 PM.

Poster Tour W1**Guide: Matthew Farrer (USA)**

- P01.01 Calmodulin regulation of L-type calcium channels in SNc DA neuron culture
- P01.05 Dietary administration of paraquat for 13 weeks does not result in a loss of dopaminergic neurones in the substantia nigra of mice
- P01.13 Role of MAPT variation in Parkinsonian disorders
- P01.14 Exome sequencing of Norwegian families with PD reveals novel gene mutations
- P01.18 Household organophosphorus pesticide use and Parkinson's disease
- P01.20 Exploring the impact of Parkinson disease (PD) susceptibility loci in older persons without PD
- P01.21 The complex interaction of LRRK2 with the cytoskeleton

Poster Tour W2**Guide: Ted Dawson**

- P03.03 Protein misfolding cyclic amplification (PMCA) as an alpha-synuclein anti-aggregation drug-screening tool
- P03.05 Smoking and Parkinson's disease: nicotine binds to alpha-synuclein and causes large conformational changes which may prevent it from misfolding
- P03.06 14-3-3 chaperone protein modulates alpha-Synuclein aggregation and toxicity
- P04.04 The role of intramolecular interactions in parkin activation in vivo
- P04.11 Mutant LRRK2 expression induces calcium dysregulation and dendritic mitophagy
- P05.02 High Cortical LB burden and ABeta pathology in Lewy Body Dementia and Parkinson's disease Dementia
- LBP05 Tau oligomers as novel therapeutic target for PD and neurodegenerative synucleinopathies

Poster Tour W3**Guide: Etienne Hirsch**

- P09.01 Neuroprotection and neurorescue properties of Sitagliptin in 6-hydroxydopamine rodent model of Parkinson's disease
- P09.03 The effect of a chronic treatment with MPEP, an mGlu5 receptor antagonist, on brain basal ganglia D1/D2 receptors, preproenkephalin/preprodynorphin mRNA levels and ERK/Akt signaling pathways in de novo parkinsonian monkeys
- P10.01 A functional magnetic resonance imaging approach towards understanding the circuit-level effects of deep brain stimulation
- P10.03 Quantitative evaluation of hypokinesia in Parkinson's disease using sensor gloves
- P11.01 Dose-dependent therapeutic effects of FK506 on dopaminergic neurodegeneration and neuroinflammation in a viral vector-based alpha-synuclein rat model for Parkinson's disease
- P11.07 Unilateral 6-OHDA lesion and Dopa administration in Nur77 knockout rats reveal an important role of this transcription factor in Parkinson's disease and its treatment
- P11.08 Selective knockout of the vesicular GABA transporter (VGAT) in the motor cortex completely protects against MPTP-induced lesioning in mice

Poster Tour W4**Guide: Alice Templin**

- P28.08 Tai Chi, zumba, drumming and golf: an integrative approach to promote PD wellness
- P28.16 Effects of resistance training on bradykinesia, functional performance and disease severity in individuals with Parkinson's disease
- P28.17 Development of a community-based Nordic walking program for persons with Parkinson's disease
- P29.04 Comparative biomechanics from ice skating and regular terrain locomotion amongst people living with Parkinson's disease
- P29.11 School "Health" in the lives of patients with Parkinson's disease
- P32.02 Shared decision making in current treatment choice in advanced Parkinson's disease
- P32.03 Equal options; shared decision? Development of a decision aid for treatment choice in advanced Parkinson's disease

Poster Tour W5

Guide: Anne-Louise Lafontaine

- P34.03 Developing a network of interdisciplinary Parkinson's rehabilitation teams in nontraditional settings: providing high-quality treatment to populations in underserved settings
- P34.04 The relationship between patient age and resource utilization among newly diagnosed Parkinson's disease patients
- P34.05 Our experience developing a service for in-patients with Parkinson's
- P34.07 Does a specialist Parkinson's unit improve outcomes for hospitalised Parkinson's patients?
- P37.01 Multidisciplinary care in professional networks for Parkinson's disease

Poster Tour W6

Guide: Michel Panisset

- P12.09 Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP-103-020)
- P12.22 Gender differences in non-motor symptoms in early, drug naïve Parkinson's disease
- P13.05 Motor, cognitive and affective characteristics of new-fallers compared to non-fallers in an incident cohort of Parkinson's disease
- P13.06 Gait predicts decline in attention over 18 months in an incident cohort of Parkinson's disease
- P14.05 The Relation between Obsessive Compulsive Behaviors and PARKIN Genotype
- LBP14 The clinical features of asymptomatic, first degree relatives of Ashkenazi Jewish Parkinson patients, carriers of the G2019S mutation in the LRRK2 gene

Poster Tour W7

Guide: Daniel Weintraub

- P15.01 Personality and depression: Factors that influence reported quality of life among PD patients
- P15.02 Impact of Parkinson's disease on social role function: Multi-faceted disability
- P15.03 A new paradigm in neuropsychological assessment: Motor Imagery. A pilot Study with Parkinson's disease patients
- P15.19 Vitamin D in Parkinson's disease
- P16.03 High intensity exercise improves skeletal muscle mitochondrial function corresponding with reduced fatigability in Parkinson's disease
- P16.04 Treatment of obstructive sleep apnea with continuous positive airway pressure improves non-motor symptoms in Parkinson's disease patients
- P16.05 Focus Group and Quantitative Assessment of Sleep and Fatigue in Patients with Parkinson's Disease
- LBP19 The Roles of Dorsal and Ventral Striatum in Stimulus-Response Learning: Implications for Parkinson's Disease

Poster Tour W8

Guide: Anthony Lang

- P20.01 Changes in troublesome dyskinesia and its relationship with dose in advanced Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion
- P20.03 Taq1A polymorphism improves Dopamine Agonist therapeutic response in Parkinson's Disease
- P20.07 Effects of levodopa on gait variability of backward walking in Parkinson's disease
- P20.12 Safety analyses from open-label clinical trials of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease: Events not related to device or procedure
- P20.13 Effective treatment of Parkinson tremor using kinematics to optimize Botulinum neurotoxin type A injection
- P20.23 Pharmaceutical Quality of Seven generic Levodopa/Benserazide Products compared with original Madopar® / Prolopa®

Poster Tour W9

Guide: Margarita Makoutonina

- P22.31 | AmbuloSono: a sensorimotor contingent musical walking program for people living with Parkinson's disease
- P22.50 | Neurocognitive rehabilitation with motor imagery vs treadmill training for freezing of gait in Parkinson's disease. A randomized controlled study
- P22.61 | A unique community Group Rehabilitative Exercise and Therapy (GREAT) program for people with Parkinson's disease
- P22.68 | The effectiveness of occupational therapy in Parkinson's disease
- LBP24 | The effect of dopaminergic medication on muscle performance in people with Parkinson's disease-related fatigue
- LBP25 | The role of optic flow on locomotion in young adults during overground walking
- LBP27 | Central components of quadriceps fatigue are dopamine dependent

Poster Tour W10

Guide: Terry Ellis

- P22.01 | Impact of freezing of gait on self-perceived balance confidence for functional activities in people with Parkinson's disease
- P22.17 | Treatment effects of Attention Process Training for an individual with Parkinson's disease: A single-subject study
- P22.29 | The impact of high intensity exercise on outcome in people with Parkinson's disease: A systematic review
- P22.48 | The type of secondary task matters in dual task walking during the Timed Up and Go
- P22.49 | Pre-stepping postural preparation in patients with Parkinson's disease with and without freezing of gait
- P22.51 | Assessment of gait therapy effectiveness in the patients with Parkinson's disease on the basis of three-dimensional movement analysis
- P22.54 | Home-based gait improvement in Parkinson's disease: using video to support self-cueing

Poster Tour W11

Guide: Jon Stamford

- P24.04 | Initial choice of dopaminergic therapy in the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Longitudinal Study-1 (LS-1)
- P24.06 | Apokyn for morning akinesia trial (AM IMPAKT)
- P24.11 | A cohort study of Parkinson's disease in British Columbia
- P24.12 | Efficacy, safety and tolerability of rasagiline as add-on to suboptimal dopamine agonist monotherapy in Parkinson's disease (PD): The ANDANTE study
- P24.14 | Effects of a community-based balance program on enhancing the balance performance in people with Parkinson's disease
- P24.16 | Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study)

Poster Tour W12

Guide: Hayley Carpenter

- P38.01 | The chain that bonds not binds – a project in awareness
- P38.07 | Pass the baton for Parkinson's awareness and fundraising program
- P38.19 | The social movement: building the More Than Motion™ Facebook community for people living with Parkinson's disease
- P39.02 | The effect of Medicare Part D on Parkinson's disease patients: a four year retrospective study
- P39.03 | The accomplishments and challenges of international Parkinson advocacy: social history, literature review and call to action
- P39.04 | Policy Advocacy on Parkinson's Diseases in Nepal
- P41.03 | Parkinson's UK Research Support Network – working together to find a cure

POSTER TOURS

5:15 PM – 6:45 PM Exhibit Hall (220C)

Presenters of featured posters will be present during poster tours to explain their work. Tours take place at the end of the day on Tuesday and Wednesday. Tour sign-up required (see sheets in front of main entrance to Exhibit Hall at 220D). Meeting point at first poster of tour at 5:15 PM.

Poster Tour T1

Guide: Louis Tan

- P01.02 Analysis of Gene Expression in Peripheral Blood of Patients with Parkinson's Disease
- P01.10 COMT × DRD4 epistasis impacts cognitive flexibility during the Trail Making Test
- P01.11 PARK18 SNP is Associated with Differential Expression of Major Histocompatibility complex II in Healthy Controls and Parkinson's Disease Patients
- P01.16 Investigation of PD brain DNA for SNCA (alpha-synuclein) mutations, and cellular studies of the recently reported H50Q
- P01.17 Revisiting Smoking and Parkinson's: Marker, Cause or Effect?
- P01.22 Identification of LRRK2 G2019S modifiers of disease penetrance
- P02.16 Lewy body fractions from patients with Parkinson's disease initiate-synuclein-dependent neurodegeneration in mice and non-human primates

Poster Tour T2

Guide: Jeffrey Kordower

- P06.02 Identification of cis- and trans-regulatory elements and signaling pathways in parkin gene expression – A genomic fugu parkin model
- P06.03 Molecular mechanisms of neurodegeneration in the En1+/- mouse model of Parkinson's disease
- P06.05 A reverse engineered Parkinson's disease gene regulatory network identifies RGS2as a direct modulator of LRRK2 activity
- P06.08 Synergistic effects of mGluR5 antagonism and 5-HT1A/1B agonism in a rat model of L-DOPA-induced dyskinesia
- P06.13 Longitudinal in vivo imaging in a novel model of Parkinson's disease in minipig
- P06.18 Parkinsonian features in aging GFAP.HMOX1 transgenic mice overexpressing human HO-1 in the astroglial compartment
- P06.24 LRRK2 G2019S knock in Mice display progressive alterations in dopamine release and metabolism
- LBP11 Striatal and extrastriatal dopamine correlates with cognition in Lewy body disorders: an 11C altoprane PET study

Poster Tour T3

Guide: Mark Guttman

- P28.04 In the Clinic, in Education and in the Community: A Capacity Building Strategy for Comprehensive Supportive Services and Wellness Programs through Community Partnership
- P28.06 Community wellness for people with Parkinson's
- P28.07 Nutritional status correlates with non-motor and motor symptoms of Parkinson's disease: A cross-sectional analysis in 143 patients
- P28.09 A continuous care model: education to rehabilitation to wellness
- P28.12 Improving nutritional status in Parkinson's disease and the effects on Parkinson's disease symptoms

Poster Tour T4

Guide: Lucie Lachance

- P30.02 Awareness of Parkinson's Disease Questionnaire (APDQ) in an Urban Asian setting
- P31.01 The impact of clinical symptoms on quality of life in patients with advanced stage Parkinson's disease
- P31.04 The Parkinson Atlas: transparency in medical practice variations in PD care in the Netherlands
- P31.05 Comparison of the psychological symptoms and disease-specific quality of life (QoL) between early- versus late-onset Parkinson's disease patients
- P31.08 Factors, disabling patients on the early stages of Parkinson's disease
- P31.12 Does home-visiting improve quality of life of those living with Parkinson's disease living in rural areas? – a program evaluation
- P31.14 Patient-centered care in the Parkinson centers of excellence: a multicenter study

Poster Tour T5

Guide: Ruth Hagestuen

- P36.07 An evaluation of the Occupational Therapy Memory Group run for those with mild cognitive impairment in Parkinson's
- P36.08 Applying Integrated Chronic Care Management model using LSVT BIG and LSVT LOUD protocol framework for care of people with PD in the home
- P36.09 Twenty-five years of discovery: A longitudinal study of Parkinson support groups
- P36.10 The effect of a music cue on gait and quality of life in Parkinson's: a case study
- P36.12 Home-based training with Nintendo Wii Fit and Balance Board in Parkinson's disease. Is it a tool for self-management motor activities in long term care ?
- P36.16 Expressive Writing improves Psychosocial Functioning of Patients with Parkinson's Disease and their Caregivers

Poster Tour T6

Guide: Laura Marsh

- P15.07 The impact of treatment response to cognitive-behavioral therapy on different clusters of depressive symptoms in Parkinson's disease
- P15.09 Mild Cognitive Impairment in Parkinson's Disease is linked with Extensive Cortical Thinning during Longitudinal Analysis
- P15.11 Initial Results of a Clinical Trial comparing a Neurocognitive Intervention to Supportive Therapy in Individuals with Parkinson's Disease
- P15.12 Does rTMS enhance memory retention in Parkinson's Disease (PD)?
- P15.13 Working memory and facial expression recognition in Parkinson's disease individuals
- P15.16 Exercise for the mind: Investigating the effects of exercise on cognition in Parkinson's disease
- LBP20 Associations of Cognitive Domain Impairments and Gait in Parkinson's Disease

Poster Tour T7

Guide: Thomas Gasser

- P19.02 Effect of Dopamine Receptor Binding Agents on Dopamine Transporter (DaT) Scan Result
- P19.03 A large Turkish Parkinson Pedigree with alpha-Synuclein Duplication: Blood Expression Biomarkers elucidate predictive Diagnostics and Pathway
- P19.04 A Novel Blood-Brain Barrier Permeable PET Ligand for Parkinson's Disease
- P19.05 Longitudinal striatal atrophy during Parkinson's progression
- P19.07 Metabolomic changes associated L-DOPA induced dyskinesia in a MPTP primate model of Parkinson's disease and the effect of DHA or plasmalogen precursor administration
- P19.17 Influence of Dopamine Transporter (DaT) scan on medical management in movement disorders specialists: Cleveland Clinic experience

Poster Tour T8

Guide: Roger Barker

- P17.08 Targeted next-generation sequencing for Parkinson's disease
- P21.02 Case report: transplantation of fetal porcine ventral mesencephalic cells (FPVMC) for Parkinson's disease (PD): results and pathology
- P21.04 Long-term safety considerations of deep brain stimulation in treatment of Parkinson's disease
- P21.08 Modulation of glutamate receptors in dyskinetic MPTP monkeys receiving unilateral subthalamicotomy
- P21.15 Social support and motor outcomes after Deep Brain Stimulation in patients with Parkinson's Disease

Poster Tour T9

Guide: Bastiaan Bloem

- P22.10 | A novel approach to testing freezing of gait in patients with Parkinson's disease: The clover test
- P22.32 | Using the SpeechVive to treat speech impairments in Parkinson's disease
- P22.47 | Changes in vowel (co)articulation following intensive voice treatment (LSVT) in Parkinson's disease
- P22.55 | The impact of physical environmental barriers on accessibility problems- veryold people with self-reported Parkinson's disease versus controls
- P22.59 | Efficacy of mental practice mnemonic coupled with physical practice in improving gait of patients with Parkinson's disease
- P22.65 | Development of an intelligent bicycle for rehabilitation in Parkinson's disease
- LBP26 | Long-term Observation of Speech and Language in Patients with Parkinson's Disease under Continuous Levodopa/Carbidopa Intestinal Gel Therapy

Poster Tour T10

Guide: Marten Munneke

- P22.21 | Benefits of task-specific learning-principled practice to improve freezing of gait for individuals with Parkinson disease in a small group community setting. A case series study
- P22.34 | European physiotherapy guidelines for people with Parkinson's disease
- P22.44 | Test-retest and inter-rater reliability of the mini-BESTest in mild to moderate Parkinson's disease – a clinical approach
- P22.46 | An acute Parkinson's therapy pathway; bridging the gap between hospital and home
- P22.60 | A vision of improved postural stability in Parkinson's disease: enhancing balance through visual training under dual-task conditions
- P23.02 | Nicotine and nicotinic receptor drugs reduce L-dopa-induced dyskinesias in anonhuman primate model of Parkinson's disease

Poster Tour T11

Guide: Sara Riggare

- P25.01 | 3D Sensors, the New Paradigm for Assessing Movement Disorders
- P25.04 | Can single-leg stance time be used to assess bilateral progression of Parkinson's disease?
- P25.06 | Dual-task performance assessment (DTPA): A novel test for assessing motor and cognitive performance during dual-task
- P25.08 | Measures of quality care reveal large variation across NPF Centers of Excellence
- P26.07 | SENSE-PARK: measuring Parkinson in the home environment in an objective, continuous and minimally obtrusive fashion

Poster Tour T12

Guide: Israel Robledo

- P40.02 | Managing Parkinson's disease symptoms while hospitalized for non-PD related conditions
- P42.01 | Experiencing Parkinson's Disease and the Reward System: the point of view of aninformed patient
- P42.03 | Not only an old person's disease
- P42.04 | How the nonprofit sector can help people living with Parkinson's receive quality voice treatment: two successful models
- P42.08 | Clinical profile of Parkinson's disease patients with pneumonia
- P42.09 | The effect of STN-DBS's laterality on voice and perception of speechintelligibility of patients with Parkinson's disease
- P42.11 | ParkNC: a referral network for enhanced Parkinson's disease care throughout North Carolina
- LBP32 | Achieving the impossible together